Cefovecin

Skin, soft tissue and urinary tract infections in pets caused by Gram-positive and Gram-negative bacteria are common infectious diseases in animal clinical practice. Such infections are prone to recurrence and require a long administration cycle. Traditional cephalosporins require frequent injection, resulting in low treatment compliance. Cefovecin is a third-generation cephalosporin API exclusively for animals. It exerts a bactericidal effect by inhibiting the synthesis of bacterial cell wall mucopeptides, and has ultra-long-acting pharmacokinetic characteristics. The effective plasma concentration can be maintained for 14 days after a single administration. It is mainly used in scenarios such as pyoderma, urinary tract infection and surgical infection prevention in dogs and cats, and is an important choice for anti-infective treatment in pet clinical practice.

The global market size of pet cephalosporin anti-infective drugs had exceeded 1.8 billion US dollars in 2023, with a compound annual growth rate maintained at around 7.2%, among which the proportion of long-acting cephalosporin products is increasing year by year. With the rapid expansion of the domestic pet medical market, the annual growth rate of market demand for cefovecin exceeds 15%. At present, the supply side is dominated by imported original research APIs, and a number of domestic enterprises have laid out generic drug R&D. As the requirement for accessibility of pet drugs increases, the domestic substitution space of this API is very considerable.

The original research enterprise of cefovecin is Pfizer, and the original research trade name is Convenia. Its core compound patent expired in the United States in 2021, and the patent in Europe expired in 2022. The main dosage forms approved by the original research are lyophilized powder for injection, with two specifications of 80mg/ml and 160mg/ml, which have been included in the FDA reference preparation catalog for animal drugs. There is no cefovecin preparation approved for marketing in China yet, and no valid A-status registration number has been found on the CDE API registration platform for the time being. At present, the generic drug R&D of this variety is in the pre-declaration stage. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of cefovecin impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They meet the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully support the relevant needs in the links of generic drug R&D, quality research and daily quality control of this variety.